Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma

The European Respiratory Journal 2024 January 25 [Link] Joanna Obacz, Jose Antonio Valer, Reshma Nibhani, Taylor S Adams, Jonas C Schupp, Niki Veale, Amanah Lewis-Wade, Jasper Flint, John Hogan, Giuseppe Aresu, Aman S Coonar, Adam Peryt, Giulia Biffi, Naftali Kaminski, Hayley Francies, Doris M Rassl, Mathew J Garnett, Robert C Rintoul, Stefan J Marciniak Abstract…

Read More

Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1

International Journal of Cancer 2024 January 11 [Link] Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, Hidetomo Himuro, Rieko Matsuura, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada Abstract The selection of highly specific target antigens is critical for the development of clinically efficient and…

Read More

Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesothelioma

JTCVS Open 2023 September 14 [Link] Kenichi Okubo, Hironori Ishibashi, Ryo Wakejima, Shunichi Baba, Ayaka Asakawa, Hiroshi Seshima Abstract Objective: To evaluate the efficacy of multimodality treatment including extended pleurectomy/decortication (P/D) and hyperthermic intraoperative chemotherapy (HIOC) with cisplatin for malignant pleural mesothelioma (MPM), we investigated the pharmacokinetics of platinum, adverse events after HIOC, and survival…

Read More

Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma

Modern Pathology 2024 January 5 [Link] Christopher A Febres-Aldana, Jason C Chang, Achim A Jungbluth, Prasad S Adusumilli, Francis M Bodd, Denise Frosina, Jerica A Geronimo, Enmily Hernandez, Helen Irawan, Michael D Offin, Natasha Rekhtman, William D Travis, Chad Vanderbilt, Marjorie G Zauderer, Yanming Zhang, Marc Ladanyi, Soo-Ryum Yang, Jennifer L Sauter Abstract 9p21 deletions…

Read More

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort

ERJ Open Research 2023 December 27 [Link] Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby Abstract Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma…

Read More

Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT

World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…

Read More

Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells

Cancer Science 2023 December 26 [Link] Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Combination immunotherapy with multiple immune checkpoint inhibitors (ICIs) has been approved for various types of malignancies, including malignant…

Read More

Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma

Pharmaceuticals 2023 November 21 [Link] Lale Evsen, Patrick J Morris, Craig J Thomas, Michele Ceribelli Abstract The hippo signaling pathway is a central tumor suppressor cascade frequently inactivated in selected human cancers, leading to the aberrant activation of TEAD transcription factors. Whereas several TEAD auto-palmitoylation inhibitors are currently in development, a comprehensive assessment of this…

Read More

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial

Clinical Cancer Research 2023 December 18 [Link] Francesco Passiglia, Luisella Righi, Paolo Bironzo, Angela Listì, Giovanni Farinea, Enrica Capelletto, Silvia Novello, Alessandra Merlini, Giorgio V Scagliotti Abstract Introduction: Treatment of homologous recombination repair deficient (HRD)-tumours with PARP inhibitors has the potential to further increase tumour immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present…

Read More

PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma

Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…

Read More